John Milligan, Gilead’s new CEO, will face many challenges, including pressures over competition and pricing for the company’s hepatitis C pills. Since the company started launching costly new hepatitis C treatments in 2013, Gilead sales have risen nearly 3½ times to $32.2 billion last year.
from WSJ.com: US Business http://ift.tt/25JctfX
via IFTTT
No comments:
Post a Comment